Rekha Chaudhuri

The Airway Transcriptome in Type 2 Cytokine Biomarker‐High and ‐Low Severe Asthma

Jiashu Shen, Rekha Chaudhuri, Bicknell, Adel H. Mansur et autres

Severe asthma is a heterogeneous disease. The mechanisms driving airway pathology when type 2 (T2) cytokine activity is suppressed remain poorly understood. This study aimed to provide insight by identifying the airway molecular pathways of T2 biomarker-high and -low severe asthma. We …

gb, se (code pays fourni par la source)

Development of the UK Severe Asthma Registry as a performance-monitoring quality improvement platform

Paul Pfeffer, Thomas Brown, Adriana Kramer Fiala Machado, Mitesh Patel et autres

The UK Severe Asthma Registry (UKSAR) was established to facilitate research and quality improvement including performance monitoring across UK severe asthma centres. We here describe its development and refinement for the latter of those objectives. The selection of performance outcome measures for …

gb (code pays fourni par la source)

Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry

Evangelia Fouka, Aruna T. Bansal, Kjell Erik Julius Håkansson, Fabienne Jaun et autres

se, dk, ch, be, hr, cz, ee, fr, de, us, kw, gr, hu, is, it, lv, lt, lu, nl, pl, pt, ro, rs, si, es, tr, gb (code pays fourni par la source)

Asthma exacerbation profile of benralizumab for severe eosinophilic asthma (the BenRex study): a multicentre, prospective cohort study

Jennifer Logan, Kirsty Martin, Lynsey Gillespie, Alex McConnachie et autres

BACKGROUND: Benralizumab, an interleukin-5 receptor α antagonist, depletes blood eosinophils, reducing exacerbations of severe asthma by approximately 50% versus placebo. In this study, we aimed to characterise mechanisms underlying exacerbations occurring on benralizumab. METHODS: BenRex, a multicentre, prospective cohort study, recruited participants …

gb (code pays fourni par la source)

Managing multimorbidity in severe asthma: comparison of resources and perspectives between severe asthma specialists and general respiratory physicians across Europe

Dace Matisa, Aruna T. Bansal, Saša Rink, Anna Freeman et autres

Background: Multimorbidity refers to the presence of multiple coexisting conditions, but is often underappreciated in the context of severe asthma (SA) management. We sought to identify differences in approaches to multimorbidity management in SA, variability in access to multidisciplinary team (MDT) resources, …

lv, si, gb, nl, se, ro, it, be, fr, hu, is, pt, de, ie, ch, ba, lt, rs, pl, tr, us, hr, by, dk (code pays fourni par la source)

Genome-wide association study of asthma with high treatment burden and/or worse outcomes defined using electronic healthcare data in UK Biobank

Noemi N. Piga, Michael A. Portelli, Nick R. G. Shrine, Jing Chen et autres

Background In ∼10% of asthma patients, symptoms remain uncontrolled despite maximal treatment, representing an unmet clinical need. The causal variants, genes and pathways underlying genetic risk factors have not been fully elucidated, and it is unclear whether there are unique genetic risk …

gb, us, ca, nl, au (code pays fourni par la source)

Multimorbidity phenotypes and associated characteristics in severe asthma: an observational study of European severe asthma registries

Anna Freeman, Saša Rink, Aruna T. Bansal, Betty Frankemölle et autres

Background: The phenotypic nature of multimorbidity in severe asthma is poorly understood. Our aims in this study were to define multimorbidity phenotypes and their characteristics in severe asthma across Europe by identifying and characterising co-aggregation of comorbidities. Methods: Cross-sectional patient data were …

gb, si, nl, se, ca, lv, ro, it, be, fr, hu, is, pt, lt, rs, pl, tr, hr, by, dk (code pays fourni par la source)

Adverse outcomes in young adults with severe asthma: results from the UK Severe Asthma Registry

LJ Holmes, Charlene Redmond, Liam Heaney, John Busby et autres

Background: Chronic disease in young adults is associated with poor healthcare engagement, poor health-related outcomes and high-risk behaviours. However, there are minimal data regarding the outcomes of young adults with severe asthma. In this study we aimed to assess asthma characteristics and …

gb, ca (code pays fourni par la source)

P302 The virtual patient stratifies patient-specific response to bronchial thermoplasty with high accuracy

Himanshu Kaul, RJ Russell, M Ola, Matt Richardson et autres

Introduction Bronchial Thermoplasty (BT) is an available therapy for severe asthma. However, we are unable to stratify a priori clinical responders limiting its widespread adoption. Aim To establish BT’s clinical benefit and identify responder attributes to enable clinical decision-making. Methods We pooled …

gb, ca, nl, fr, de, ch, us (code pays fourni par la source)

Improvements in FEV1 and St George’s Respiratory Questionnaire (SGRQ) at 4 and 16 weeks on benralizumab are strongly associated with clinical remission at 1 year

Jennifer K. Logan, Kirsty Wetherall, Lynsey Gillespie, Alex McConnachie et autres

Introduction: Remission is now an aspiration for asthma patients on biologics, although there is no agreed definition. Predicting the likelihood of remission at an early stage on treatment would improve precision therapy. Aims: To identify the characteristics at 4 and 16 weeks …

gb, us, au (code pays fourni par la source)

Stringent American (ATS/ACAAI/AAAAI) endorsed 6-component definition of asthma remission is not achievable in a real-world benralizumab cohort

Jennifer K. Logan, Kirsty Wetherall, Lynsey Gillespie, Alex McConnachie et autres

Introduction: Goals for asthma treatment with biologics have progressed to clinical remission. General expert consensus1 is that remission should encompass absence of oral corticosteroids [OCS], well controlled symptoms and stable FEV1. A working group from the American Thoracic Society and College and …

gb, us, au (code pays fourni par la source)

The airway transcriptome in type2 cytokine biomarker-high, -intermediate and -low severe asthma

Emanuele Marchi, Rekha Chaudhuri, Steve Bicknell, Adel Hasan Mansur et autres

Background: Type 2 (T2) cytokines (IL-4, -5, and -13) drive eosinophilic inflammation in asthma. However, molecular mechanisms differentiating T2-high and T2-low asthma remain underexplored. This study aims to elucidate the transcriptomic signatures and pathways associated with these T2 phenotypes. Methods: Patients with …

gb, us (code pays fourni par la source)